These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 9416950)
1. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950 [TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL). Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R; Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827 [TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Lacourcière Y Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232 [TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension. Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446 [TBL] [Abstract][Full Text] [Related]
6. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932 [TBL] [Abstract][Full Text] [Related]
7. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension. Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Tikkanen I; Omvik P; Jensen HA J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133 [TBL] [Abstract][Full Text] [Related]
9. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357 [TBL] [Abstract][Full Text] [Related]
10. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785 [TBL] [Abstract][Full Text] [Related]
11. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Byyny RL; Merrill DD; Bradstreet TE; Sweet CS Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Malmqvist K; Kahan T; Dahl M Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401 [TBL] [Abstract][Full Text] [Related]
13. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. von Vigier RO; Zberg PM; Teuffel O; Bianchetti MG Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blockers. A new class of antihypertensive drugs. Velasquez MT Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875 [TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383 [TBL] [Abstract][Full Text] [Related]
17. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. Franke H J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010 [No Abstract] [Full Text] [Related]
18. Irbesartan treatment in hypertension. Brown MJ Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies. Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]